74 results about "Cycloastragenol" patented technology

The invention discloses a preparation method and application of cycloastragenol. The preparation method of the cycloastragenol comprises the following steps: by using astragaloside or astrasieversianin as a raw material, oxidizing, reducing, hydrolyzing, extracting and purifying to obtain high-purity cycloastragenol. The method is simple to operate, gentle in condition, good in product quality and high in yield. The cycloastragenol can be applied to preparation of anticancer adjuvant therapeutic medicine. An anticancer adjuvane therapeutic medicine prepared by using the cycloastragenol as a pharmaceutical active ingredient has the anticancer adjuvant therapeutic effect of enhancing the anticancer therapeutic effect, reducing the toxicity of the anticancer medicine, preventing and treating the neutropenia caused by the anticancer medicine therapy.

The invention relates to a method for producing and refining cycloastragenol with a purity greater than or equal to 95%. Using astragaloside IV as a raw material, through two-phase enzymatic hydrolysis, extraction, and recrystallization, cycloastragenol products with a purity greater than or equal to 95% are obtained. Compared with the existing cycloastragenol production method, the present invention has simple production process, mild reaction conditions, high reaction conversion rate, is more suitable for large-scale production, and solves the problem of astragaloside IV being hydrolyzed under acid-base conditions. The easy ring opening leads to the difficulty of generating astragalol.

The invention provides a method for efficiently preparing cycloastragenol. The method sequentially comprises the following steps of A, fermenting: filling total saponins of radix astragali seu hedysari into a fermentation tank, injecting a buffer solution containing compound enzyme into the fermentation tank until a sample is completely immersed, stirring and then performing catalytic fermentation; B, regulating alkali: after catalysis is ended, regulating fermentation liquid obtained in the step A into an alkali solution, and standing for one hour; C, performing counter-current extraction: pumping the fermentation liquid obtained in the step B and an extraction agent into a counter-current extraction tower for extracting; D, performing vacuum concentration on a mixed solution, which is obtained by extracting, of the cycloastragenol and the extraction agent. The method provided by the invention has the beneficial effects that firstly, a compound enzyme fermentation technology and a continuous counter-current extraction technology are combined for extracting and purifying to obtain high-purity cycloastragenol, and high conversion rate and higher purity of products are realized; secondly, the finishing time of the whole process does not exceed eight hours; the temperature is low in the operation process, so that biological activity of the cycloastragenol is guaranteed; the production efficiency is improved, energy consumption is reduced, and the production cost is reduced by 50 percent or above 50 percent.

The invention provides a cycloastragenol extract. A preparation method of the cycloastragenol extract comprises the steps that coarse astragalus membranaceus powder is extracted by using an alkaline alcohol water solution with a pH value of 11-13 to obtain a coarse astragaloside extract; the obtained coarse astragaloside extract is enriched and purified through macroporous resin to obtain an astragaloside extract; the obtained astragaloside extract is subjected to Smith degradation to obtain the cycloastragenol extract. For cycloastragenol extract preparation, an optimum extraction method is obtained through multiple times of tests conducted on the pH value, sodium periodate dosage and methanol concentration in the extraction conditions. The method is good in reproducibility, simple and easy to operate. The prepared cycloastragenol extract can obviously retard senility hurt of H2O2 to PC12 cells, and improve cell vitality, and the cycloastragenol extract obtained by adopting the preparation method has certain anti-aging activity and can be applied to preparation of anti-aging medicines and health-care products.

The invention discloses a method for preparing cycloastragenol by means of biological conversion and degradation of astragaloside. The method is characterized in that astragaloside serves as a substrate, and cycloastragenol is prepared by means of fermentation of the strain of Absidia sp.CGMCC 3.2834. According to the method for preparing cycloastragenol by means of biological conversion and degradation of astragaloside, a microbiologic fermentation technology is adopted for degrading astragaloside to obtain high-purity cycloastragenol, the technology is simple and easy to carry out, the cost is low, the conversion rate of cycloastragenol reaches 60% or above, the purity reaches up to 95% or above, and the conversion specificity is high; the whole technological process is conducted at normal temperature and atmospheric pressure, the required equipment conditions are low, and the method is suitable for mass production.

The invention provides a high-temperature-resistant compound enzyme and applications of the high-temperature-resistant compound enzyme. The high-temperature-resistant compound enzyme is composed of beta-glucosidase and beta-xylosidase. The compound enzyme provided by the invention is strong in specificity, and can completely convert astragaloside, so that the conversion recovery rate of cycloastragenol is improved. The whole process is completed within 3h, the preparation process of cycloastragenol is greatly shortened, and the production efficiency is improved; in the reaction process, the reagents including strong reducing agents, oxidizing agents, strong acid and the like do not need to be added, so that the environmental pollution is reduced; self-making of the two enzymes can be realized, thus the production cost is greatly reduced, and the process is suitable for industrial production.

The present invention belongs to the field of medicine, and particularly relates to uses of cycloastragenol in preparation of chronic renal failure treatment drugs. According to the present invention, cycloastragenol is the aglycone of astragaloside A, and has advantages in biological membrane permeation and gastrointestinal tract absorption compared to astragaloside A due to the relatively small molecular weight and the strong lipophilicity, and the test results show that cycloastragenol can change various physiologic indexes of chronic renal failure rates so as to provide great application prospects in the treatment of chronic renal failure.

The invention relates to the technical field of biotransformation, in particular to a method for preparing cycloastragenol through double-enzyme compounding transformation of astragaloside. Accordingto the method, the astragaloside is used as a substrate, xylosidase and glucosidase are subjected to double-enzyme compounding, then xyloside bonds at the C3 position of the substrate and glucoside bonds at the C6 position of the substrate are broken through one-step hydrolysis, and the cycloastragenol is obtained. The purity of the obtained cycloastragenol can reach 98% or above, and the method is easy to operate, free of pollution, milder in reaction temperature, clear in enzyme conversion mechanism, and wider in enzyme substrate adaptability and is suitable for industrial production.

The invention supplies eye-astragalus alcohols compounding ramification that could improve the water solubility of parent substance compounding. The invention could improve the biology availability of the drug, and make it possible to develop the constituent into oral dosing agent. It could be used in curing cardiovascular disease and cerebrovascular disease, myocarditis, nephritis, diabetes, rheumatism and hepatitis. It could be also used to anti virus.

The invention provides cycloastragenol-6-O-beta-D glucoside monohydrate and a crystal thereof and preparation methods of the cycloastragenol-6-O-beta-D glucoside monohydrate and the crystal thereof and a drug composition. Studies show that the prepared cycloastragenol-6-O-beta-D-glucoside hydrate containing crystal water is white crystalline powder, can exist stably and is convenient to store and transport and to prepare drug preparations. The cycloastragenol-6-O-beta-D-glucoside containing crystal water is easier to dissolve in water and alcohols solvents, has good room temperature storage stability and lower moisture absorption and is convenient for preparing the directly dissolved and absorbed preparations.

The invention discloses a synthesis method of astragaloside. The synthesis method of the astragaloside comprises the following steps of using protecting groups R1 for protecting 3-site hydroxy and 6-site hydroxy of cycloastragenol; after using protecting groups R2 for protecting 16- site hydroxy and 25- site hydroxy, removing the protecting groups R1 for the 3- site hydroxy and the 6- site hydroxy, and obtaining a compound 4; using a protecting group R3 for protecting 3- site hydroxy of the compound 4, and obtaining a compound 5; carrying out glycosylation on the compound 5, then removing the protecting group R3 for the 3- site hydroxy, continuously carrying out glycosylation, and obtaining a compound 8; removing all protecting groups to obtain the astragaloside. According to the synthesis method of the astragaloside provided by the invention, the astragaloside is high-efficiently and high-stereoselectively prepared, a gap in the prior art is filled, and the progresses of the activity mechanism research of astragalus membranaceus saponins and the medicinal development thereof are greatly improved.

The invention relates to a method for preparing cycloastragenol through microorganism mixed fermentation, transformation and degradation of astragaloside iv. Two strains of fusarium proliferatum 0821(CGMCC NO.16482 ) and Fusarium verticillioides 0213 (CGMCC NO.16481 ) which are screened out are used, the astragaloside iv is used as a substrate, and through mixed fermentation of the two strains, the cycloastragenol is prepared. A technique for mixed fermentation with two microorganisms is adopted to degrade the astragaloside iv so as to obtain the cycloastragenol high in purity. The technological flow is simple, the cost is low, and the entire technological process is performed at normal temperature and normal pressure. The required equipment condition is low, the method is suitable for mass production, the conversion rate of the final cycloastragenol is as high as 80% or above, and the purity is as high as 95% or above.

The invention provides monoglucoside injection of cycloastragenol and a preparation method and application of the injection. The injection consists of monoglucoside of the cycloastragenol, non-aqueous solvent, solubilizer and water for injection. According to the injection, the solubilizer and the non-aqueous solvent are utilized to perform combined solubilization on the single glucoside of the cycloastragenol; and compared with the single solubilization of the non-aqueous solvent, the combined solubilization can be used for reducing the dosage of the non-aqueous solvent, relieving the stimulus of the non-aqueous solvent on a patient, and effectively avoiding the medicine precipitation in a medicine diluting process.

The invention discloses a method for promoting in-vitro amplification of an umbilical cord blood T cell and maintaining a high-proportion TSCM subpopulation. The method comprises the steps that cycloastragenol, a cell factor IL-7 and a cell factor IL-15 are combined and added into an in-vitro culture solution of the T cell to promote the amplification of the T cell and maintain the high-proportionTSCM subpopulation. The method for promoting the in-vitro amplification of the umbilical cord blood T cell and maintaining the high-proportion TSCM subpopulation has the advantages that the high-proportion TSCM cell subpopulation can be maintained while the low-concentration CAG combined with the IL-7 and the IL-15 to promote the amplification of the umbilical cord blood derived T cell is successively explored; the novel in-vitro culture method lays an experimental foundation for the in-vitro long-term culture of the T cell and an immunization therapy containing a CAR-T cell therapy.

The invention discloses a complex microbial inoculant for regulating gynecological micro-ecological balance. The complex microbial inoculant is prepared from lactobacillus crispatus, lactobacillus salivarius SIL1 (Lactobacillus salivarius SIL1) and other acceptable drug excipients. The invention further discloses a preparation method of the complex microbial inoculant. The preservation number of the Lactobacillus crispatus strain is CGMCC No. 6364, and the preservation number of the lactobacillus salivarius SIL1 is CCTCC M2010281. The complex microbial inoculant can be prepared into oral liquid or fermented food, preferably capsules, bacterial powder, milk tablets, fermented food and the like. Preferably, the complex microbial inoculant also comprises cycloastragenol.

The invention provides a cycloastragenol crystal form B as well as a preparation method and application thereof. The cycloastragenol crystal form B provided by the invention has higher purity and better chemical stability, and a better dissolution and release effect can be achieved when the crystal form B is prepared into a pharmaceutical preparation, and meanwhile, the preparation method of cycloastragenol is simple, convenient and easy to industrialize.

The invention belongs to the technical field of organic chemical drug preparation, and provides a cycloastragenol crystal form E as well as a preparation method and application thereof. The cycloastragenol crystal form E provided by the invention has higher purity and better chemical stability, the crystal form E has better dissolution and release behaviors when being prepared into a pharmaceutical preparation, and meanwhile, the preparation method of the cycloastragenol is simple, convenient, easy to industrialize and high in production adaptability.

The invention belongs to the technical field of organic chemical medicine preparation, and specifically relates to a cycloastragalol crystal form A and a preparation method thereof. The crystal form uses Cu-Kalpha radiation, and X-ray powder diffraction (X-RPD) represented by a 2theta angle has characteristic diffraction peaks when 2theta is equal to 4.9 +/-0.2 degrees, 9.8 +/-0.2 degrees, 13.2 +/-0.2 degrees, 15.7 +/-0.2 degrees and the like. The crystal form has good chemical stability and crystal form purity, large-scale preparation is easy, and the preparation method is simple to operate,can be better suitable for preparation of pharmaceutical preparations and large-scale production, and has broad application prospects.

The invention discloses a method for preparing 6-O-glucose-cycloastragenol by transforming astragaloside through aspergillus carbonarius, and particularly relates to a method for preparing the 6-O-glucose-cycloastragenol in a transformed manner by using the astragaloside as a substrate to ferment through aspergillus carbonarius. CICC 41254 on the premise of using a proper amount of astragalus root powder as an inducer. Fermentation liquor obtained by fermentation is extracted through water saturated n-butyl alcohol, is subjected to column chromatography on silica gel and is recrystallized with ethanol, and finally, the 6-O-glucose-cycloastragenol product with the purity being 95% or above is obtained finally. The 6-O-glucose-cycloastragenol is prepared by a microbe transformation method. The method has the characteristics that the astragaloside as a substrate is almost transformed totally, the transformation rate is high, the method is simple and practicable, the cost is low, and the method is pollution-free to environment, and is suitable for industrialized production.

The invention discloses an application of cycloastragenol in prevention and treatment of myocardial fibrosis. The cycloastragenol is applied to one of the following steps (a1) and (a2): (a1) preparinga product for preventing and/or treating myocardial fibrosis; (a2) preventing and/or treating myocardial fibrosis. The cycloastragenol can effectively inhibit a myocardial collagen volume fraction increase, an expression level increase of myocardial fibrosis marker genes in myocardial tissues, an mRNA expression level increase of ANF genes in myocardial tissues, an expression level increase of related inflammatory cytokine genes and the degree of infiltration of inflammatory cells in the heart of the body due to the myocardial fibrosis, and the symptom of irritating dry cough does not occur in experiments of the cycloastragenol. In summary, the cycloastragenol plays an important role in preventing and treating the myocardial fibrosis, and has a great application prospect in the preventionand treatment of the myocardial fibrosis.

The invention discloses application of cycloastragenol to preparation of a drug for inhibiting abdominal aortic aneurysm. The invention provides application of cycloastragenol to preparation of products for preventing and/or treating abdominal aortic aneurysm, and/or to prevention and/or treatment abdominal aortic aneurysm. The invention also provides a drug for preventing and/or treating abdominal aortic aneurysm. The active component of the drug is cycloastragenol. The drug for inhibiting abdominal aortic aneurysm is safe and has low toxicity and strong pharmacological action; the raw material of the drug is widely available and low in price, and can be prepared through hydrolysis of the astragalus extract astragaloside; a preparation method for the drug is low in cost, simple in processand high in yield; and the curative effect of the drug is definite. According to the invention, a novel drug source is provided for preventing, diagnosing, detecting, protecting, treating and researching abdominal aortic aneurysm diseases, and is easy to promote and apply and capable of generating enormous social and economic benefits in a short period of time.

The invention belongs to the technical field of organic chemical drug preparation, and provides a cycloastragenol crystal form D and a preparation method and application thereof. The cycloastragenol crystal form D provided by the invention has higher purity and better chemical stability, the crystal form D has better dissolution and release behaviors when being made into a pharmaceutical preparation, and meanwhile, the preparation method of the cycloastragenol is simple, convenient, easy to industrialize and high in production adaptability.

The invention relates to a method for preparing cycloastragenol by fermenting and converting astragaloside IV by using fusarium palustris 0821 (CGMCC (China General Microbiological Culture Collection Center) No.16482). The invention also relates to a method for preparing the cycloastragenol by using the fusarium palustris 0821). According to the method disclosed by the invention, the cycloastragenol is prepared by utilizing the screened Fusarium proliferum and taking astragaloside as a substrate through fermentation. According to the method, astragaloside is converted to obtain high-purity cycloastragenol by utilizing a Fusarium profermentum fermentation technology, the whole technological process is carried out at normal temperature and normal pressure, required equipment conditions are low, the method is suitable for mass production, the conversion rate of the cycloastragenol reaches 80% or above finally, and the purity of the cycloastragenol reaches 95% or above finally.